Navigation Links
Contrave in Medical News

Orexigen(R) Therapeutics Announces Second Quarter 2009 Financial Results

...gen, and the results demonstrate the potential for contrave to help patients in their battle against obesity,"...ight loss." Recent Highlights contrave Orexigen announced that the three remaining Phase 3 trials in the contrave Obesity Research, or COR, program met their co-pri...

-Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments-

...and 17.1%, respectively (ITT, p<0.001). contrave patients in COR-I and COR-II on Contrave32 had mea...le the 18.9% of patients on placebo (p<0.001). contrave patients also showed a 0.6% reduction in HbA1c fro...cerides. Additional analyses indicate that contrave patients experienced reductions in the frequency a...

Orexigen(R) Therapeutics Announces In-Licensing of Key Patents to Further Strengthen its Intellectual Property Estate for Contrave(R)

...ity with, Contrave, the potential to commercialize contrave and the expected impact of the license agreement w...yses of data from the remaining clinical trials of contrave may produce negative or inconclusive results, or m...al trials may not be predictive of future results; contrave may not receive regulatory approval on a timely ba...

Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer

...mpletion of the remaining three Phase 3 trials for contrave (naltrexone sustained release (SR)/bupropion SR) a...lment, timing and completion of clinical trials of contrave and Empatic, the potential to obtain regulatory approval for, and effectively treat obesity with, contrave and Empatic, and the scope and duration of protect...

Pipeline for New Obesity Therapies is Focus of New Report

...; Solvay / BMS), rosonabant (E-6776; Esteve), AVE-1625 (Sanofi-Aventis), LH-21 (Instituto de Quimica Medica), Qnexa (phentermine / topiramate; Vivus), contrave (bupropion / naltrexone; Orexigen), Empatic (bupropion SR + zonisamide SR; Orexigen), Meridia (sibutramine; Abbott), lorcaserin (APD356; Arena), Byett...
Contrave in Medical Technology

Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23

SAN DIEGO, June 21, 2007 /PRNewswire-FirstCall/ -- Orexigen(TM) Therapeutics, Inc. , a biopharmaceutical company focused on the treatment of central nervous system disorders with an initial focus on obesity, today announced that the Company will present data about its lead obesity product candidat...

Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results

..., a biopharmaceutical company focused on the treatment of obesity, plans to announce the results of the three remaining Phase 3 clinical trials in the contrave program on Monday, July 20, 2009 before the markets open. The announcement will be followed by a live webcast and conference call at 8:00 a.m. Eastern...

Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team

...nticipates announcing the results from the first Phase 3 clinical trial for contrave in January. About Orexigen Therapeutics Orexigen Therapeuti...ng, execution, completion and announcement of results of clinical trials of contrave and the potential to obtain regulatory approval for, and effectively treat ...

Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)

...ne SR, pooled 24 week data from the Phase 2 NB-201 contrave trial (N=212) with naltrexone IR was compared with...24 week blinded data from a series of four Phase 3 contrave trials (N=3,943 evaluable patients), all employing...dverse event (13.8% versus 16.0%). -- Across the contrave Phase 3 trial experience to date, only 7.6% of all...

Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule

... compared to the legacy naltrexone IR formulation. contrave currently is being studied in four Phase III clini...r, and effectively treat obesity with, Empatic and contrave and the enrollment, timing and completion of clinical trials of contrave and Empatic. The inclusion of forward-looking stat...
Contrave in Biological Technology

Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions

...ating control experienced by patients treated with contrave versus placebo (p< 0.01), as well as previously...f cardiometabolic risk. "NB-302 results show that contrave initiates and sustains weight loss and can improve...due to its unique effects on brain reward centers, contrave may allow patients to better control their eating ...

Orexigen(R) Therapeutics Announces Jay Hagan as Senior Vice President, Corporate Development and Strategy

...s and commercialization strategy for lead products contrave (naltrexone sustained release (SR)/bupropion SR), ... approval for, and effectively treat obesity with, contrave or Empatic. The inclusion of forward-looking stat...luding, without limitation: the clinical trials of contrave may produce negative or inconclusive results, or m...

Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results

...re collecting the last of our patient data for the contrave Phase 3 development program. We believe that if the data is positive, contrave should have the ability to address a tremendously ...lso a director of AMAG Pharmaceuticals, Inc. contrave The...

Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program

... his role, Dr. Scaife will lead the development of contrave (naltrexone sustained release (SR)/bupropion SR), ...luding, without limitation: the clinical trials of contrave may produce negative or inconclusive results, or m...al trials may not be predictive of future results; contrave may not receive regulatory approval on a timely ba...

Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints

...hly statistically significant (p<0.001). contrave was generally well tolerated by patients. The overall safety profile of contrave was consistent with its individual components, nal...ely in patients for over 20 years. Treatment with contrave was not associated with increases in symptoms of d...

Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)

.../Cowley methods patent will provide protection for contrave through mid 2024. "The issuance of this pat...operty coverage." About Contrave(R) contrave is an investigational oral weight loss medication ...wn as the reward center). In fact, we believe that contrave may be the first treatment for obesity to target t...

Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results

...elopment expenses in connection with the Company's contrave Phase 3 clinical trials, related proprietary produ... important results from our lead obesity programs, contrave and Empatic. We are eagerly awaiting data from our...ieve that we remain on track for an NDA filing for contrave in late 2009." Recent Highlights -- Orexigen i...
Other Tags
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... natural forms, such as organically raised chickens and eggs. Eating organic foods and ... chickens is cleaner and more environmentally friendly than production chicken farming. Choosing home ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... cancer enterprise of Hospital Corporation of America (HCA), as it further expands its ... announced today. , With this new partnership, OncLive’s editorial and marketing teams ...
(Date:7/1/2015)... ... - (PRWEB) July 01, 2015 , ... Lisa Keys, the widow of U.S. ... 15-16th (MSG Keys’ birthday) in memory of her late husband and all of America’s ... of the Bronze Star Medal, died during a Special Forces training exercise in December ...
(Date:7/1/2015)... ... July 01, 2015 , ... RowdMap Inc. is a proud ... paper: “Pro-actively Identifying the High-Cost Patient Population: Insights from the Health Care Transformation ... http://www.hcttf.org/resouces-tools . , The Healthcare Transformation Task Force is a group of ...
(Date:7/1/2015)... ... July 01, 2015 , ... A Priority ... published a top ten list they hope will guide future mesothelioma research. Surviving ... read it now. , More than 450 mesothelioma patients, caregivers, and ...
Breaking Medicine News(10 mins):Health News:Chicken Coop Condo Offer New Chicken Coop Designs 2Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 2Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 3Health News:Wife of Fallen Special Forces Soldier to Host Nationwide ‘Virtual 5K’ for Charity 2Health News:Wife of Fallen Special Forces Soldier to Host Nationwide ‘Virtual 5K’ for Charity 3Health News:A Population Based Approach to Pay for Value: RowdMap, Inc. Contributes to Health Care Transformation Task Force White Paper 2Health News:A Population Based Approach to Pay for Value: RowdMap, Inc. Contributes to Health Care Transformation Task Force White Paper 3Health News:New Report Identifies Top 10 Mesothelioma Research Priorities, According to Surviving Mesothelioma 2
(Date:6/23/2015)... , June 23, 2015   MedNet ... that supports the entire spectrum of clinical research, ... ™ , the company,s intuitive, flexible ... awarded a Silver 2015 Stevie® Award by the ... Products & Services Website category.  The American Business ...
(Date:6/23/2015)... Fla. , June 23, 2015 /PRNewswire/ ... management and authentication solutions, today announced enhanced functionality ... multi-factor authentication solution.  The enhancements build on ... of the DigitalPersona Altus platform and provide ... compatibility. In today,s environment of ...
(Date:6/17/2015)... HILDEN , Deutschland und GERMANTOWN, Maryland ... Investigator ®   Produktlinie mit ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime ... neue STR-Testkits der Produktlinie Investigator ... DNA-Spuren in den Markt eingeführt. Die neuen Kits zur ...
Breaking Biology News(10 mins):MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6
Other Contents